PT  - JOURNAL ARTICLE
AU  - Kogan, Nicole E.
AU  - Gantt, Shae
AU  - Swerdlow, David
AU  - Viboud, Cécile
AU  - Semakula, Muhammed
AU  - Lipsitch, Marc
AU  - Santillana, Mauricio
TI  - Leveraging Serosurveillance and Postmortem Surveillance to Quantify the Impact of COVID-19 in Africa
AID  - 10.1101/2022.07.03.22277196
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.03.22277196
4099  - http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277196.short
4100  - http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277196.full
AB  - Background The COVID-19 pandemic has had a devastating impact on global health, the magnitude of which appears to differ intercontinentally: for example, reports suggest 271,900 per million people have been infected in Europe versus 8,800 per million people in Africa. While Africa is the second largest continent by population, its reported COVID-19 cases comprise <3% of global cases. Although social, environmental, and environmental explanations have been proposed to clarify this discrepancy, systematic infection underascertainment may be equally responsible.Methods We seek to quantify magnitude of underascertainment in COVID-19’s cumulative incidence in Africa. Using serosurveillance and postmortem surveillance, we constructed multiplicative factors estimating ratios of true infections to reported cases in African nations since March 2020.Results Multiplicative factors derived from serology data – in a subset of 12 nations – suggested a range of COVID-19 reporting rates, from 1 in 630 infections reported in Kenya (May 2020) to 1 in 15 infections reported in South Africa (November 2021). The largest multiplicative factor, 3,795, corresponded to Malawi (June 2020), suggesting <0.05% of infections captured. A similar set of multiplicative factors for all nations derived from postmortem data points toward the same conclusion: reported COVID-19 cases are unrepresentative of true infections, suggesting a key reason for low case burden in many African nations is significant underdetection and underreporting.Conclusions While estimating COVID-19’s exact burden is challenging, the multiplicative factors we present provide incidence curves reflecting likely-to-worst-case ranges of infection. Our results stress the need for expansive surveillance to allocate resources in areas experiencing severe discrepancies between reported cases, projected infections, and deaths.Summary Here we present a range of estimates quantifying the extent of underascertainment of COVID-19 cumulative incidence in Africa. These estimates, constructed from serology and mortality data, suggest that systematic underdetection and underreporting may be contributing to the seemingly low burden of COVID-19 reported in Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by institutional research funds from Pfizer Inc. (NEK, SG, ML, and MS). The content is solely the responsibility of the authors and does not necessarily represent the official views of Pfizer Inc. NEK was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number 2T32AI007535.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: -SeroTracker (https://serotracker.com/en/Explore): serosurveillance data -Mwananyanda et al. (https://pubmed.ncbi.nlm.nih.gov/33597166/): postmortem surveillance data -Gill et al. (https://www.medrxiv.org/content/10.1101/2022.03.08.22272087v1.full): postmortems surveillance dataI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://serotracker.com/en/Explore